Premium
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy – a randomized, double‐blind, placebo‐controlled multicentre trial
Author(s) -
MADISCH A.,
MIEHLKE S.,
NEUBER F.,
MORGNER A.,
KUHLISCH E.,
RAPPEL S.,
LEHN N.,
BAYERDÖRFFER E.,
SEITZ G.,
STOLTE M.
Publication year - 2006
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.02778.x
Subject(s) - medicine , omeprazole , placebo , helicobacter pylori , gastroenterology , gastritis , randomized controlled trial , surgery , pathology , alternative medicine
Summary Background An association between Helicobacter pylori infection and lymphocytic gastritis has been postulated. Aim To assess the long‐term effect of H. pylori eradication therapy on lymphocytic gastritis in a double‐blind, placebo‐controlled, multicentre trial. Methods Patients with lymphocytic gastritis were randomized to receive either 1‐week triple therapy for eradication of H. pylori or omeprazole plus placebo. Endoscopy and histology was performed at baseline and after 3 and 12 months. Patients of the omeprazole/placebo group with persistent lymphocytic gastritis after 12 months received crossover open‐label triple therapy. Results Fifty‐one patients were randomized. Intention‐to‐treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83.3% vs. 57.7%, 95% CI for RR: 0.8–2.8, P = 0.06). After 12 months, the healing rate of lymphocytic gastritis was significantly higher after triple therapy compared with omeprazole/placebo (intention‐to‐treat 95.8% vs. 53.8%, 95% CI for RR: 1.1–3.5, P = 0.01). All patients ( n = 5) who received crossover triple therapy, showed healing of lymphocytic gastritis after further 12 months. Conclusion Our study demonstrates that 1‐week triple therapy aiming at eradication of H. pylori leads to a complete and long‐lasting resolution of lymphocytic gastritis in the majority of patients.